Moderna (MRNA -0.80%) has delivered the pivotal cancer result investors were waiting for, while BioNTech Se (BNTX +0.57%) offers greater financial flexibility and a broader oncology pipeline. The question is whether Moderna's stronger clinical proof deserves its valuation premium, or whether BioNTech's multiple paths to success create the more attractive long-term setup.
Stock prices used were the market prices of Sept. 11, 2026. The video was published on Sept. 28, 2026.




